With a median follow-up of 9 years, discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic phase chronic myeloid leukaemia (CML) was reported in 43% of 548 evaluable CML patients, in a population-based setting. Patients interrupting TKI therapy outside a clinical trial setting had good outcomes.
Dr Hjalmar Flygt (Uppsala University Hospital, Sweden) presented data extracted from the Swedish CML registry about patients stopping TKI therapy outside of clinical trials in chronic phase CML . Studies have shown that 40-50% of patients with a deep molecular response (DMR, defined as MR4.0 or lower) successfully remained TKI treatment-free. In the current Swedish Guidelines for CML, stopping TKI therapy can be considered in patients treated with a TKI ≥5 years and an MR4.0 or lower for at least 2 years.
CML patients diagnosed between 2007-2012 (n=584) were analysed, of whom 234 of the 548 evaluable patients (43%) had...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Asciminib monotherapy in Ph+ CML: major molecular responses Next Article
Patients with lower-risk MDS benefit from imetelstat »
Table of Contents: EHA 2020
Plasma Cell Dyscrasias
Bench-to-Bedside Science from the Presidential Symposium
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.